Prevention of cholesterol gallstones by the potent cholesterol absorption inhibitor ezetimibe in gallstone-susceptible C57L/J mice

Wang, H. H.; Portincasa, Piero; Wang, D. Q.-H.

doi:10.1007/978-1-4020-6252-0_28

Cited by 2 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in contrast to the gallstone composition in recent studies from sub-Saharan Africa [15] and China [16,17]. Based on the findings of this study, a potential homogenous target population in Germany for non-surgical intervention [12,13] for the prevention of cholesterol stones would be obese individuals with a BMI > 30, for which approximately 95% of cholesterol gallstones were observed in both males and females.…”

Section: Resultsmentioning

confidence: 53%

“…Significant progress has been made both in the genetics of gallstone formation [1,8] and in the molecular biology of bile excretion [9-11]. Consequently, this mechanistic knowledge may be lead to novel non-surgical therapeutic or preventive strategies, as for instance shown by the prevention of cholesterol gallstone formation in a mouse model by FXR agonists [12] or the cholesterol absorption inhibitor ezetimibe [13]. Gallstones, however, are heteroneous both in terms of their composition and their pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany

Schafmayer

Hartleb²,

Tepel

et al. 2006

BMC Gastroenterol

View full text Add to dashboard Cite

Background: Gallstones represent a prevalent and costly health problem. The changing epidemiology and the emerging non-surgical interventions for gallstone disease necessitate the definition of target populations for future therapies. This study aimed to define patterns of gallstone composition and identify demographic predictors of gallstone composition in a large sample of symptomatic gallstones from Northern Germany.

show abstract

Section: Resultsmentioning

confidence: 53%

Section: Introductionmentioning

confidence: 99%

Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany

Schafmayer

Hartleb²,

Tepel

et al. 2006

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Genetic variants can impair the FGF19 signalling [ 38 ]. Genetic variants in NPC1L1 , regulating cholesterol absorption in the canalicular membrane and in the enterocyte in humans might also be involved in in cholesterol hypersecretion, although studies with the specific NPC1L1 inhibitor ezetimibe argue against this possibility [ 39 – 44 ] and need to be further investigated. Rapid phase transitions of biliary cholesterol means that excess of biliary cholesterol is not solubilized in bile by bile acids and phospholipids at equilibrium [ 45 ].…”

Section: Pathogenesis Of Gallstonesmentioning

confidence: 99%

Metabolic dysfunction-associated gallstone disease: expecting more from critical care manifestations

et al. 2023

View full text Add to dashboard Cite

About 20% of adults worldwide have gallstones which are solid conglomerates in the biliary tree made of cholesterol monohydrate crystals, mucin, calcium bilirubinate, and protein aggregates. About 20% of gallstone patients will definitively develop gallstone disease, a condition which consists of gallstone-related symptoms and/or complications requiring medical therapy, endoscopic procedures, and/or cholecystectomy. Gallstones represent one of the most prevalent digestive disorders in Western countries and patients with gallstone disease are one of the largest categories admitted to European hospitals. About 80% of gallstones in Western countries are made of cholesterol due to disturbed cholesterol homeostasis which involves the liver, the gallbladder and the intestine on a genetic background. The incidence of cholesterol gallstones is dramatically increasing in parallel with the global epidemic of insulin resistance, type 2 diabetes, expansion of visceral adiposity, obesity, and metabolic syndrome. In this context, gallstones can be largely considered a metabolic dysfunction-associated gallstone disease, a condition prone to specific and systemic preventive measures. In this review we discuss the key pathogenic and clinical aspects of gallstones, as the main clinical consequences of metabolic dysfunction-associated disease.

show abstract

Prevention of cholesterol gallstones by the potent cholesterol absorption inhibitor ezetimibe in gallstone-susceptible C57L/J mice

Cited by 2 publications

References 26 publications

Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany

Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany

Metabolic dysfunction-associated gallstone disease: expecting more from critical care manifestations

Contact Info

Product

Resources

About